Why Automated Cell Culture Is Transforming Precision, Scalability, and Lab Efficiency
According to a new report published by Polaris Market Research, the global Automated Cell Culture market was valued at USD 20.99 billion in 2025 and is projected to reach USD 63.15 billion by 2034, expanding at a CAGR of 13.02% during the forecast period.
Market Overview:
The market has witnessed steady growth in recent years, driven by rising demand for biologics, growing adoption of laboratory automation across research and biomanufacturing environments, and expanding investment in cell therapy and regenerative medicine. Biopharmaceutical firms are increasingly turning to robotic cell culture systems and AI-powered cell manipulation tools to improve reproducibility, reduce contamination risk, and boost throughput across drug discovery and biologics production pipelines.
Growing collaboration between technology providers and life-sciences companies, along with supportive research funding in major economies, is further accelerating adoption of bioprocessing automation. Market participants are prioritizing innovation, capacity expansion, and strategic partnerships to strengthen their competitive positioning, and demand is expected to remain resilient through the forecast period as precision medicine and cell therapy pipelines continue to scale.
Key Market Insights:
The market generated an estimated USD 20.99 billion in base-year 2025 revenue, with the automated systems segment leading at a 29.20% share on the strength of its role in high-throughput laboratory and manufacturing workflows.
North America led the global landscape with a 48.30% revenue share in 2025, while Asia Pacific is projected to register the fastest growth through 2034, supported by rising biotechnology infrastructure investment across China, India, and South Korea.
Adoption of AI-driven cell culture automation is accelerating; in January 2026, Automata formed a strategic alliance with Cellvoyant to build an AI-based closed-cell culture workflow system using predictive analytics alongside lab automation tools.
Market Dynamics:
Driver: Rising global demand for biologics is strengthening the need for efficient, automated cell culture systems that ensure consistency across production runs.
Driver: The need for reproducibility in research and bioprocess development is driving adoption of automated cell handling and intelligent cell culture solutions that minimize human variability.
Restraint: High capital costs associated with robotics, software, and facility modifications limit adoption among small labs and research organizations operating under budget constraints.
Restraint: Integrating automated systems into existing laboratory infrastructure presents operational complexity, and a shortage of trained personnel can further slow adoption in smaller facilities.
Opportunity: Expanding biomanufacturing infrastructure across emerging markets, supported by government-backed biotechnology initiatives, presents significant headroom for automated cell culture adoption.
Opportunity: Strategic collaborations between automation technology providers and life-sciences companies are opening new avenues for scalable, AI-integrated bioprocessing platforms.
Competitive Landscape:
The market is marked by a concentrated structure, with firms across life sciences and laboratory automation competing to deliver advanced, integrated solutions. Competitive positioning is shaped by system integration capability, speed of operation, usability, and adherence to laboratory standards, with demand from biopharmaceutical manufacturing and research institutions continuing to influence vendor strategy. Leading companies are investing in research and development to introduce AI-enabled, GMP-compliant platforms, while partnerships, software integrations, and product launches remain common strategies for strengthening market position.
Key Players:
Becton, Dickinson and Company
Beckman Coulter, Inc.
Bio-Rad Laboratories, Inc.
Biospherix Ltd.
Cell Culture Company, LLC
Corning Incorporated
F. Hoffmann-La Roche Ltd.
Hamilton Company
Hitachi High-Tech Corporation
Lonza Group Ltd.
Merck KGaA
Miltenyi Biotec B.V. & Co. KG
PromoCell GmbH
Sartorius AG
Tecan Trading AG
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
Recent Developments:
January 2026: Automata formed a strategic alliance with Cellvoyant to develop an AI-based closed-cell culture process workflow system combining predictive analytics with lab automation tools.
December 2025: Emory University introduced CellXpress.ai, an automated robotic and AI-imaging cell cultivation technology, in the U.S. for high-throughput organoid research.
May 2024: Sinfonia Technology Co., Ltd. delivered its CellQualia Intelligent Cell Processing System in Japan to automate cell culture for regenerative medicine manufacturing.
Market Segmentation:
By Product Outlook (Revenue, USD Billion, 2021-2034)
Automated Systems
Consumables
Software
By Application Outlook (Revenue, USD Billion, 2021-2034)
Drug Discovery
Stem Cell Research
Biopharmaceutical Production
By End-User Outlook (Revenue, USD Billion, 2021-2034)
Biopharmaceutical Companies
CROs & CDMOs
Academic & Research Institutes
Regional Insights:
North America: Held a 48.30% market share in 2025, supported by a strong presence of biopharmaceutical companies and advanced research infrastructure; in December 2025, Emory University introduced CellXpress.ai, an automated robotic and AI-imaging cell cultivation technology, for high-throughput organoid research in the U.S.
Asia Pacific: Projected to witness the highest CAGR during the forecast period, driven by rising biotechnology infrastructure investment in China, India, and South Korea, including India's Bio-RIDE initiative, which has allocated USD 1.1 billion toward biomanufacturing and biofoundry capabilities.
Europe: The second-leading regional market, propelled by regulatory structures that facilitate bioprocessing adoption; in December 2025, the European Commission introduced the Biotech Act to strengthen Europe's biotechnology sector with a focus on healthcare applications.
Latin America & Middle East and Africa: Represent emerging growth pockets, with automation solutions increasingly introduced across laboratories and healthcare institutes to improve the efficiency of cell culturing procedures.
Future Outlook:
The Automated Cell Culture Market is expected to witness continued expansion as laboratories increasingly adopt automation to improve reproducibility, efficiency, and throughput. Growing demand for high-quality cell-based research in drug discovery, regenerative medicine, and biotechnology is likely to support market development. Integration of robotics, artificial intelligence, and advanced laboratory information systems is expected to enhance automated workflows.
Future growth is also likely to be supported by increasing investment in pharmaceutical and biotechnology research infrastructure. Automated systems can help reduce manual errors and standardize complex cell culture procedures across research environments. As technologies become more flexible, scalable, and accessible, adoption is expected to broaden across academic, clinical, and industrial laboratories.
Comments